Axogen Announces Leadership Transition as CEO Karen Zaderej Retires from Company in January 2025
ALACHUA and TAMPA, Fla. Jan. 4, 2024 - Axogen, Inc. (NASDAQ: AXGN), a pioneering force in developing and marketing groundbreaking surgical solutions for peripheral nerve injuries, has revealed its plan for a leadership transition, with President and CEO Karen Zaderej expected to retire from the company by January 2025. This strategic decision marks a significant turning point in Axogen’s journey, as it paves the way for a new leader to guide the company towards continued innovation and growth.
The organization’s Board of Directors has taken a proactive approach to ensure a smooth transition by initiating the recruitment of a new CEO through an executive recruitment firm. Ms. Zaderej, while continuing to lead the company until a successor is appointed, will eventually step down from her role and her Board duties. However, she will remain connected to Axogen in a consultative capacity for an additional nine months, lending her expertise and support during the leadership transition process and the submission of the Biologics License Application (BLA) for the revolutionary Avanceâ„¢ Nerve Graft.
Although the planned transition is slated for no later than January 5, 2025, the timeline may be expedited depending on the appointment of a new CEO. Axogen’s commitment to ensuring a seamless change in leadership demonstrates the organization’s focus on maintaining momentum and driving progress in its mission to transform the lives of patients with peripheral nerve injuries.
Axogen’s groundbreaking surgical solutions have revolutionized the treatment landscape for peripheral nerve injuries, offering hope to countless individuals affected by this debilitating condition. By providing innovative options such as the Avanceâ„¢ Nerve Graft, Axogen has demonstrated its unwavering dedication to improving patient outcomes and enhancing the quality of life for those living with peripheral nerve injuries.
With its global presence and relentless commitment to innovation, Axogen has earned a reputation as a leader in the field. The retirement of CEO Karen Zaderej presents a unique opportunity for the company to identify a successor who will build upon the organization’s success and drive further advancements in peripheral nerve injury treatment.
Axogen’s focus on finding a suitable replacement ensures that the organization will be in capable and visionary hands in the years to come. The collaboration between Ms. Zaderej and the incoming CEO during the leadership transition will guarantee a seamless continuation of Axogen’s mission, cementing its status as a groundbreaking force in surgical solutions for peripheral nerve injuries.
Comments